Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis

Annals of the Rheumatic Diseases

Volumn 64, Issue 4, 2005, Pages 630-633

  Ostendorf, B ^a   Iking Konert, C ^a   Kurz, K ^a   Jung, G ^a   Sander, O ^a   Schneider, M ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTIMALARIAL AGENT; AZATHIOPRINE; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; MESALAZINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ROFECOXIB;

ADULT; ARTHRITIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; EUROPEAN CONSENSUS LUPUS ACTIVITY MEASUREMENT; FEMALE; HUMAN; IMMUNOLOGY; INJECTION SITE REACTION; MALE; PNEUMONIA; PRIORITY JOURNAL; SCORING SYSTEM; SEROLOGY; SKIN MANIFESTATION; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; UPPER RESPIRATORY TRACT INFECTION; VISUAL ANALOG SCALE;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PAIN MEASUREMENT; PILOT PROJECTS; RECEPTORS, INTERLEUKIN-1; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX; SIALOGLYCOPROTEINS;

EID: 16344374294     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.025858     Document Type: Article

References (14)

1. Dubois EL, Tuffanelli DL. Clinical manifestations of systemic lupus erythematosus. JAMA 1964;190:104-11.
2. Ostendorf B, Scherer A, Specker C, Modder U, Schneider M. Jaccoud's arthropathy in systemic lupus erythematosus: differentiation of deforming and erosive patterns by magnetic resonance imaging. Arthritis Rheum 2003;48:157-65.
3. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis. Rheum 1998;41:2196-204.
4. Firestein GS, Boyle DL, Yu C, Paine MM, Whisenand TD, Zvaifler NJ, et al. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum 1994;37:644-52.
5. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate. Arthritis Rheum 2002;46:614-24.
6. Sturfelt G, Roux-Lombard P, Wollheim FA, Dayer JM. Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus. Br J Rheumatol 1997;36:1283-9.
7. Tan EM, Cohen AS, Preis JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
8. Vitali C, Beneivelli W, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II Identification of the variables indicative of disease activity and their use in the development of an activity score. Clin Exp Rheumatol 1992;10:541-7.
9. Nayak V, Esdaile JM. The efficacy of antimalarials in systemic lupus erythematosus. Lupus 1996;(suppl 1):S23-7.
10. Sato EI. Methotrexate therapy in systemic lupus erythematosus. Lupus 2001;10:162-4.
11. Manger K, Manger B. TNF alpha-antagonists in collagen vascular disease. Z Rheumatol 2003;62:240-5.
12. Piseteky DS. Tumor necrosis factor alpha blockers and the induction of anti-DNA autoantibodies. Arthritis Rheum 2000;43:2381-2.
13. Mohan AK, Edwards ET, Cote TR, Siegel JN, Braun MM. Drug-induced systemic lupus erythematosus and TNF-alpha blockers. Lancet 2002;360:646.
14. Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, et alD. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000;43:1001-9.